Masaru Matsuda
Masaru Matsuda's purchase track record
Masaru Matsuda has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/30/2024 | ARQT | $12K | +3.3% | +8.6% | -1.8% |
| 5/31/2024 | ARQT | $7K | +30.1% | +56.0% | +14.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Halozyme Adds Jim Daly to Board Amid Q2 Earnings Review. Halozyme Therapeutics has appointed Jim Daly to its Board of Directors, a move that signals continued focus on governance and long-term strategy. This update arrives alongside a broader market review of the company's Q2 performance relative to other therapeutics firms. The stock is currently trading above its average analyst target price, with recent technical data showing confirmation near key support levels.
Transaction History
| ARQT | ▼ Sell | Open Market | 3,674 | $92K | 9/16/2026 | View on chart |
| ARQT | ▼ Sell | Open Market | 9,989 | $250K | 9/8/2026 | View on chart |
| ARQT | ▼ Sell | Open Market | 1,230 | $32K | 8/3/2026 | View on chart |
| ARQT | ▼ Sell | Open Market | 7,372 | $172K | 5/4/2026 | View on chart |
| ARQT | ▼ Sell | Open Market | 884 | $21K | 5/4/2026 | View on chart |
| ARQT | ▼ Sell | Open Market | 6,553 | $165K | 3/2/2026 | View on chart |
| ARQT | ▼ Sell | Open Market | 193 | $5K | 3/2/2026 | View on chart |
| ARQT | ▼ Sell | Open Market | 1,987 | $51K | 3/2/2026 | View on chart |
| ARQT | ▲ Buy | Grant | 37,000 | $0 | 2/27/2026 | View on chart |
| ARQT | ▼ Sell | Open Market | 3,325 | $93K | 2/27/2026 | View on chart |
| ARQT | ▼ Sell | Open Market | 7,983 | $204K | 2/2/2026 | View on chart |
| ARQT | ▼ Sell | Open Market | 8,562 | $214K | 2/2/2026 | View on chart |
| ARQT | ▼ Sell | Open Market | 19,379 | $489K | 2/2/2026 | View on chart |
| ARQT | ▼ Sell | Open Market | 4,714 | $121K | 2/2/2026 | View on chart |
| ARQT | ▼ Sell | Open Market | 1,657 | $50K | 12/1/2025 | View on chart |
| ARQT | ▼ Sell | Open Market | 989 | $28K | 11/19/2025 | View on chart |
| ARQT | ▼ Sell | Open Market | 1,561 | $44K | 11/19/2025 | View on chart |
| ARQT | ▼ Sell | Open Market | 7,165 | $177K | 11/3/2025 | View on chart |
| ARQT | ▼ Sell | Open Market | 43 | $1K | 11/3/2025 | View on chart |
| ARQT | ▼ Sell | Open Market | 36,130 | $584K | 9/4/2025 | View on chart |
| ARQT | ▼ Sell | Open Market | 6,330 | $91K | 8/4/2025 | View on chart |
| ARQT | ▼ Sell | Open Market | 1,800 | $25K | 5/28/2025 | View on chart |
| ARQT | ▼ Sell | Open Market | 5,030 | $76K | 5/2/2025 | View on chart |
| ARQT | ▼ Sell | Open Market | 3,263 | $43K | 3/3/2025 | View on chart |
| ARQT | ▲ Buy | Grant | 34,000 | $0 | 2/28/2025 | View on chart |
| ARQT | ▼ Sell | Open Market | 8,338 | $106K | 2/3/2025 | View on chart |
| ARQT | ▲ Buy | Open Market | 1,657 | $12K | 11/30/2024 | View on chart |
| ARQT | ▼ Sell | Open Market | 1,775 | $17K | 11/19/2024 | View on chart |
| ARQT | ▲ Buy | Grant | 4,875 | $0 | 11/18/2024 | View on chart |
| ARQT | ▼ Sell | Open Market | 5,015 | $44K | 11/4/2024 | View on chart |
| ARQT | ▼ Sell | Open Market | 5,220 | $47K | 8/2/2024 | View on chart |
| ARQT | ▲ Buy | Open Market | 4,000 | $7K | 5/31/2024 | View on chart |
| ARQT | ▼ Sell | Open Market | 1,775 | $16K | 5/28/2024 | View on chart |
| ARQT | ▲ Buy | Grant | 4,875 | $0 | 5/27/2024 | View on chart |
| ARQT | ▼ Sell | Open Market | 5,016 | $44K | 5/2/2024 | View on chart |
| ARQT | ▼ Sell | Open Market | 3,760 | $42K | 3/4/2024 | View on chart |
| ARQT | ▲ Buy | Grant | 74,000 | — | 2/13/2024 | View on chart |
| ARQT | ▲ Buy | Grant | 17,650 | — | 2/13/2024 | View on chart |
| ARQT | ▲ Buy | Grant | 27,900 | — | 2/13/2024 | View on chart |
| ARQT | ▲ Buy | Grant | 28,000 | $0 | 1/12/2024 | View on chart |
| ARQT | ▼ Sell | Open Market | 1,850 | $4K | 11/21/2023 | View on chart |
| ARQT | ▲ Buy | Grant | 4,875 | $0 | 11/18/2023 | View on chart |
| ARQT | ▼ Sell | Open Market | 1,830 | $14K | 5/31/2023 | View on chart |
| ARQT | ▲ Buy | Grant | 1,463 | $9K | 5/31/2023 | View on chart |
| ARQT | ▲ Buy | Grant | 4,875 | $0 | 5/27/2023 | View on chart |
| ARQT | ▼ Sell | Open Market | 1,416 | $22K | 3/2/2023 | View on chart |
| ARQT | ▼ Sell | Open Market | 18 | $297 | 3/2/2023 | View on chart |
| ARQT | ▲ Buy | Grant | 21,000 | $0 | 3/2/2023 | View on chart |
| ARQT | ▼ Sell | Open Market | 1,720 | $31K | 11/21/2022 | View on chart |
| ARQT | ▲ Buy | Grant | 4,875 | $0 | 11/18/2022 | View on chart |
| ARQT | ▼ Sell | Open Market | 1,795 | $35K | 6/2/2022 | View on chart |
| ARQT | ▲ Buy | Grant | 4,875 | $0 | 5/27/2022 | View on chart |
| ARQT | ▲ Buy | Grant | 13,300 | $0 | 3/3/2022 | View on chart |
| HALO | ▲ Buy | Option Exercise | 6,883 | $0 | 9/4/2021 | View on chart |
| HALO | ▼ Sell | Tax Withholding | 3,412 | $144K | 9/4/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
ARQT Highlights New ZORYVE Data, Wins Beauty Award, Faces Downgrade
Arcutis Biotherapeutics presented fresh clinical data for its topical drug ZORYVE at the EADV and Fall Clinical conferences, adding real‑world evidence on its use for inflammatory skin conditions. The company also received a 2026 Marie Claire Beauty Award for ZORYVE, highlighting its potential beyond dermatology. Meanwhile, analysts have downgraded the stock, citing a shrinking valuation multiple. These developments suggest the market is reassessing the company’s growth prospects.
ARQT Highlights New ZORYVE Data, Wins Beauty Award, Faces Downgrade. Arcutis Biotherapeutics presented fresh clinical data for its topical drug ZORYVE at the EADV and Fall Clinical conferences, adding real‑world evidence on its use for inflammatory skin conditions. The company also received a 2026 Marie Claire Beauty Award for ZORYVE, highlighting its potential beyond dermatology. Meanwhile, analysts have downgraded the stock, citing a shrinking valuation multiple. These developments suggest the market is reassessing the company’s growth prospects.